Every material Form 8-K Profound Medical Corp. has filed with the SEC since October 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Profound Medical Corp. said its management will take part in the Stifel 2026 Healthcare Conference in New York City on Thursday, November 12, 2026. The filing is a routine event announcement that furnishes a press release and contains no financial results, guidance, or other new business information.
President Richard Fabian is scheduled to present at 8:40 a.m. Eastern Time on November 12, 2026.
The presentation will be broadcast live and archived on the company's website.
CEO Arun Menawat and CFO Matthew Sobczyk will join Fabian for one-on-one investor meetings during the conference.
Profound Medical reported third-quarter 2026 revenue of approximately $9.8 million, up 86% year-over-year, and a net loss of about $7.7 million, or $0.21 per share, narrower than the prior-year quarter. The company projects full-year 2026 revenue of at least $25.0 million and announced that Richard Fabian will succeed Arun Menawat as CEO effective January 14, 2027.
Q3 2026 revenue of approximately $9.8 million, up 86% year-over-year; gross margin of 78% versus 74% a year earlier
Net loss improved 3% to approximately $7.7 million ($0.21 per share) from $8.0 million ($0.26 per share)
Full-year 2026 revenue projected at least $25.0 million; gross margin expected at 70% or higher
Richard Fabian becomes CEO effective January 14, 2027; Arun Menawat becomes Executive Chairman
Profound Medical's U.S. subsidiary appointed Cook Medical as a non-exclusive distributor of the TULSA-PRO system in the United States, for use with Cook's intraoperative MRI equipment. The filing does not disclose financial terms, and the initial five-year term does not start until FDA clearance for use with Cook's equipment is provided, so the deal's effect on shareholders depends on that clearance and on sales volumes.
Agreement dated October 28, 2026, effective October 23, 2026; Cook is a non-exclusive U.S. distributor of TULSA-PRO for use with Cook's iMRI equipment.
The five-year initial term begins on the date Profound provides Cook with written evidence of FDA clearance; Cook may terminate without liability if that has not occurred by April 30, 2027.
Cook will buy TULSA-PRO systems at a predetermined transfer price, while Profound keeps single-use disposables and service contract revenue from customers who buy through Cook.
The filing does not disclose purchase volumes, transfer prices or other dollar figures.
Profound Medical Corp. announced that Montel Williams will join the next Let's Huddle patient education webinar, hosted by Leonard Wheeler, on November 5, 2026. The filing contains no financial results or guidance, and the company describes the event as part of its patient education and engagement work.
Webinar is scheduled for November 5, 2026, at 3:00 p.m. ET, online at www.letshuddle.org, and advance registration is required.
Montel Williams will share his perspectives on health advocacy, resilience and informed healthcare decisions.
The company said it recently installed a TULSA-PRO system at a U.S. Department of Veterans Affairs facility.
The press release is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed under the Exchange Act.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Profound Medical Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →